Bayer Mycelex-3 "Preferred form v. Monistat-3" comparative ad not supported -- NAD.
This article was originally published in The Tan Sheet
Executive Summary
BAYER MYCELEX-3 "PREFERRED FORM v. MONISTAT-3" AD CLAIM UNSUBSTANTIATED as it "could be reasonably interpreted by consumers as a direct comparative claim between Mycelex-3 and [Johnson & Johnson's] Monistat-3, and...the data submitted by the advertiser was insufficient to support such a claim," the National Advertising Division of the Council of Better Business Bureaus concludes in its November NAD Case Reports. NAD urges Bayer either to cease using the claim or more clearly communicate that the claim is a comparison between all OTC cream yeast infection treatments versus other treatment forms and is based on total unit sales. J&J brought the claim to NAD's attention.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning